Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases

Overview

Supports collaborative research projects developing AI-driven predictive biomarkers for chronic non-communicable diseases (excluding cancer) to improve disease progression assessment and treatment response. Targets clinical researchers, healthcare professionals, and stakeholders in personalised medicine.

Who Can Apply

Consortia of legal entities established in eligible EU/EFTA countries, the UK, Switzerland, or the USA. Participation of SMEs is encouraged.

Funding Details

Maximum grant amount: €10,000,000 per project.

What Is Funded

• Development of multimodal predictive biomarkers (e.g., molecular, imaging, digital) using established AI methodologies.
• Integration of clinical, longitudinal, and real-world data (RWD) to address unmet needs in chronic non-communicable diseases.
• Clinical validation studies in independent cohorts to demonstrate biomarker utility.
• Trustworthy AI tools with performance metrics for accuracy, reliability, and bias assessment.
• Exploitation plans for research outputs and regulatory alignment strategies.
• GDPR-compliant data protection and user-friendly decision-support tools for clinicians.

Technology / Maturity Requirements

Projects must target Technology Readiness Levels (TRL) 4–6.

Key Dates

• Open date: 2027-02-09
• Deadline: 2027-04-12

Application Process (High-Level)

Two-stage process: 1. First stage: Blind evaluation (no disclosure of organisation names, logos, or personnel in abstract/Part B). 2. Second stage: Full proposal submission for shortlisted applicants.

Post-Award Obligations

• Participation in networking and joint activities (e.g., workshops, best practices) with other funded projects.
• Allocation of sufficient budget for networking activities.
• Compliance with GDPR and privacy-preserving legislation for AI and data use.

Geographic Scope & Language

Eligible countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Norway, Iceland, United Kingdom, Switzerland. Application language: English.

Notes

• Proposals must justify the clinical necessity of the biomarkers for the targeted diseases.
• Clinical studies must be led by entities in EU/EFTA or associated countries.
• Use of Copernicus/Galileo/EGNOS data is mandatory if satellite-based services are employed.
• Strong emphasis on AI trustworthiness, bias assessment, and regulatory engagement.